Edwards Lifesciences Corporatio (EW) Stock Analysis
Breakout setup
Healthcare · Medical Devices
Hold if already holding. Not a fresh buy at $85.85, but acceptable to hold if already in. Reasons: Concentration risk — Product: TAVR (74.0%); Concentration risk — Geographic: United States (58.0%).
Edwards Lifesciences develops structural heart technologies including TAVR (74% of 2025 net sales), Transcatheter Mitral and Tricuspid Therapies (9%), and Surgical heart valves (17%). In 2025, 58% of net sales came from U.S. customers; no single customer exceeded 10% of revenues.
Hold if already holding. Not a fresh buy at $85.85, but acceptable to hold if already in. Reasons: Concentration risk — Product: TAVR (74.0%); Concentration risk — Geographic: United States (58.0%). Chart setup: Golden cross, above all MAs, RSI 62, MACD bullish. Multiple concerning factors. Consider reducing position. | News modifier +2 (SELL_IF_HOLDING → HOLD_IF_HOLDING) Score 5.4/10, moderate confidence.
Passes 6/9 gates (positive momentum, clean insider activity, news boost analyst 0.70, earnings proximity 44d clear, semi cycle peak clear, materials cycle peak clear). Fails on favorable risk/reward ratio. Suitability: moderate.
Recent developments
updated 2026-06-09Recent Developments — Edwards Lifesciences Corporatio
Latest news
- NEWS EW (Edwards Lifesciences Corporation) reports Q4 2025 EPS miss, shares climb 2.45 percent amid positive investor sentime — Cổng thông tin điện tử Tỉnh Sơn La negative
- NEWS Universal Beteiligungs und Servicegesellschaft mbH Acquires 21,165 Shares of Edwards Lifesciences Corporation $EW - Mark — MarketBeat neutral
- NEWS EW DCF Analysis: Intrinsic Value $48 vs Price $78 - GuruFocus — GuruFocus negative
- NEWS Edwards Lifesciences (EW) Expected to Announce Quarterly Earnings on Wednesday - MarketBeat — MarketBeat neutral
- NEWS Zurcher Kantonalbank Zurich Cantonalbank Buys 23,305 Shares of Edwards Lifesciences Corporation $EW - MarketBeat — MarketBeat positive
Generated 2026-06-15T18:11:46Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHProductTAVR74%10-K Item 1: 'Sales of our TAVR products represented 74%, 75%, and 77% of our net sales in 2025, 2024, and 2023, respectively.'
- HIGHGeographicUnited States58%10-K Item 1: 'In 2025, 58% of our net sales were derived from sales to customers in the United States.'
Material Events(8-K, last 90d)
- 2026-05-04Item 5.02MEDIUMEdwards Lifesciences appointed Theodora Mistras as Corporate VP and CFO effective May 29, 2026, to succeed Scott B. Ullem. Mistras previously served as CFO of Viatris, Inc. No reason cited for Ullem's departure.SEC filing →
- 2026-05-08Item 5.02LOWAt the 2026 Annual Meeting on May 7, 2026, stockholders approved an amendment to the Long-Term Stock Incentive Compensation Program, increasing authorized shares by 7 million to 341.5 million total. Routine compensatory arrangement.SEC filing →
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
1 floor-breaker
Priced at a premium — multiples above sector norms. Needs delivery on growth + margins to justify.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Hold if already holding. Not a fresh buy at $85.85, but acceptable to hold if already in. Reasons: Concentration risk — Product: TAVR (74.0%); Concentration risk — Geographic: United States (58.0%). Chart setup: Golden cross, above all MAs, RSI 62, MACD bullish. Multiple concerning factors. Consider reducing position. | News modifier +2 (SELL_IF_HOLDING → HOLD_IF_HOLDING) Target $87.23 (+1.6%), stop $80.89 (−6.1%), A.R:R 0.1:1. Score 5.4/10, moderate confidence.
Take-profit target: $87.23 (+1.6% upside). Target $87.23 (+1.6%), stop $80.89 (−6.1%), A.R:R 0.1:1. Stop-loss: $80.89.
Concentration risk — Product: TAVR (74.0%); Concentration risk — Geographic: United States (58.0%); Analyst target reached - limited upside remaining.
Edwards Lifesciences Corporatio trades at a P/E of 46.4 (forward 25.5). TrendMatrix value score: 3.9/10. Verdict: Hold.
42 analysts cover EW with a consensus score of 4.0/5. Average price target: $97.
What does Edwards Lifesciences Corporatio do?Edwards Lifesciences develops structural heart technologies including TAVR (74% of 2025 net sales), Transcatheter...
Edwards Lifesciences develops structural heart technologies including TAVR (74% of 2025 net sales), Transcatheter Mitral and Tricuspid Therapies (9%), and Surgical heart valves (17%). In 2025, 58% of net sales came from U.S. customers; no single customer exceeded 10% of revenues.